Intensive early treatment can delay progression of Crohn’s: CALM study

Tight control of inflammation in early Crohn’s disease with a biologic can help prevent progression of the disease, long term follow-up of CALM study participants suggests. Patients who achieved deep remission from Crohn’s disease with biomarker-driven adalimumab treatment had a low risk of complications when followed up three years after the end of the trial, according ...

Already a member?

Login to keep reading.

© 2021 the limbic